Lv1
50 积分 2025-01-14 加入
Characterizing pulmonary adverse events associated with the immune checkpoint inhibitor avelumab: a FAERS-based pharmacovigilance study from 2013 to 2024
1个月前
已完结
Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15-Related Haplotypes
1个月前
已完结
Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15-Related Haplotypes
1个月前
已完结
Exploring Definity-related adverse reaction: A real-world pharmacovigilance study via FAERS database analysis
3个月前
已完结
Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study
4个月前
已完结
Clinical Characters and Influence Factors of Immune Checkpoint Inhibitor-related Thyroid Dysfunction
4个月前
已完结
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
5个月前
已完结
Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis
7个月前
已完结
皖公网安备34019202002308
